他汀类药物减少非进展期腺瘤向结直肠癌的进展:一项纳入187897例患者的结肠镜后研究
该回顾性队列研究利用香港全港电子医疗数据库,纳入2005至2013年接受结肠镜检查的40岁及以上患者187897例,评估他汀使用与结肠镜后3年内结直肠癌(PCCRC-3y)风险的关系。他汀使用与较低的PCCRC-3y风险相关(SHR 0.72,95%CI 0.55-0.95,p=0.018),尤其对近端癌(SHR 0.50,95%CI 0.28-0.91,p=0.022)。
要点
- 他汀使用与结肠镜后3年内结直肠癌风险降低相关,SHR为0.72(95%CI 0.55-0.95,p=0.018)。
- 近端癌风险降低更明显,SHR为0.50(95%CI 0.28-0.91,p=0.022);远端癌无显著差异。
- 年龄>60岁、女性、无糖尿病或无息肉的患者似乎从他汀中获益更多。
核心结论
- 他汀使用与较低的结肠镜后结直肠癌风险相关,尤其是近端癌。
研究设计与样本
- 回顾性队列研究,使用香港全港电子医疗数据库,纳入2005至2013年接受结肠镜检查的40岁及以上患者187897例。
主要发现
- 187897例合格受试者中,854例(0.45%)诊断为PCCRC-3y。
- 他汀使用与较低的PCCRC-3y风险相关(SHR 0.72,95%CI 0.55-0.95,p=0.018)。
- 亚组分析显示,近端癌的SHR为0.50(95%CI 0.28-0.91,p=0.022),远端癌的SHR为0.80(95%CI 0.59-1.09,p=0.160)。
- 年龄>60岁、女性、无糖尿病或无息肉的患者似乎从他汀中获益更多。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Postcolonoscopy colorectal cancer (PCCRC) accounts for up to 9% of all CRCs. Statins have been shown to be associated with a lower CRC risk. We aimed to investigate whether PCCRC risk was also lower among statin users. METHODS: This is a retrospective cohort study using a territory-wide electronic healthcare database in Hong Kong including patients aged 40 years or above who had undergone colonoscopies between 2005 and 2013. Exclusion criteria included prior colorectal cancer (CRC), inflammatory bowel disease, prior colectomy and CRC detected within 6 months of index colonoscopy. We defined statin use as at least 90-day use before index colonoscopy. Medication use was traced up to 5 years before index colonoscopy. PCCRC-3y was defined as cancer diagnosed between 6 and 36 months after index colonoscopy. Sites of CRC were categorised as proximal (proximal to splenic flexure) and distal cancer. The subdistribution HR (SHR) of PCCRC-3y with statin use was derived by propensity score matching based on covariates (including patient factors, concurrent medication use and endoscopy centre's performance). RESULTS: Of 187 897 eligible subjects, 854 (0.45%) were diagnosed with PCCRC-3y. Statin use was associated with a lower PCCRC-3y risk (SHR: 0.72; 95% CI 0.55 to 0.95; p=0.018). Subgroup analysis shows that SHRs were 0.50 (95% CI 0.28 to 0.91; p=0.022) for proximal and 0.80 (95% CI 0.59 to 1.09; p=0.160) for distal cancer. Older (>60 years) patients, women and those without diabetes mellitus or polyps appeared to benefit more from statins. CONCLUSIONS: Statins were associated with a lower PCCRC risk, particularly for proximal cancer.
引用
- Cheung KS, Chen L, Chan EW, et al. Statins reduce the progression of non-advanced adenomas to colorectal cancer: a postcolonoscopy study in 187 897 patients. Gut. 2019. PMID: 30808646. doi:10.1136/gutjnl-2018-317714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。